Real Clear Health: Consumers Deserve More Transparency from High Drug Prices

As the new legislative session begins, Congress should demand increased transparency, require flow-through of manufacturer rebates to lower consumer prices, prohibit clawbacks, and consider giving federal agencies expanded oversight responsibilities to monitor PBMs’ practices. This op-ed explains why.

FacebooktwitterredditlinkedinFacebooktwitterredditlinkedin